Next Article in Journal
A New Multi-Parametric MRI-Based Scoring System for Degenerative Cervical Myelopathy: The Severity on Imaging Myelopathy Score (SIMS)
Previous Article in Journal
Is CT Still the Gold Standard in Semicircular Canal Dehiscence? Diagnostic Value of MRI in Poschl and Stenver Planes
Previous Article in Special Issue
Efficacy and Safety of Prolonged Adjuvant Temozolomide Treatment in Glioblastoma: Prospective Study of 81 Patients Undergoing up to 101 Cycles of Treatment
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Article

Association of Health Disparities with Glioblastoma Treatment and Outcomes: Insights from a 15-Year National Cohort (2005–2020) †

1
Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA
2
Department of Neurosurgery, University of Maryland, Baltimore, MD 20742, USA
3
Penn State Cancer Institute, Penn State Health Milton S. Hershey Medical Center, Hershey, PA 17033, USA
4
Department of Neurosurgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA 17033, USA
5
Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA
*
Author to whom correspondence should be addressed.
This paper is an extended version of our preliminary findings published as a poster in Jayram, D.; Bellur, S.; Ozair, A.; Ahmad, S.; Hodgson, L.; Perez, N.F.; Podder, V.; Ganiyani, M.; Ahluwalia, M. 458P Patterns of care and clinical outcomes of patients with glioblastoma in the United States from 2005–2020: A real-world analysis. In Proceedings of the European Society for Medical Oncology (ESMO) Congress 2024, Barcelona, Spain, 13–17 September 2024.
These authors contributed equally to this work.
Brain Sci. 2025, 15(6), 556; https://doi.org/10.3390/brainsci15060556
Submission received: 1 April 2025 / Revised: 19 May 2025 / Accepted: 22 May 2025 / Published: 23 May 2025
(This article belongs to the Special Issue Editorial Board Collection Series: Advances in Neuro-Oncology)

Abstract

Background: Despite advances in glioblastoma (GBM) management, median overall survival (mOS) remains poor, and multi-modal disparities persist. We sought to evaluate trends in GBM treatment and survival outcomes from 2005–2020, with a focus on sociodemographic and geographic disparities. Methods: We conducted a retrospective US-based cohort study using the National Cancer Database (NCDB), stratifying study period into four intervals (2005–2008, 2009–2012, 2013–2016, and 2017–2020). Logistic regression was used to identified predictors of receipt of combination surgery, radiation, and chemotherapy (Sx+RT+Chemo). Kaplan–Meier and multivariable Cox proportional hazards approaches were used to assess mOS. Results: A total of 111,955 adults with GBM were included. From 2005–2008 to 2017–2020, mOS increased from 7.8 to 9.5 months, with geographically unequal gains in survival across the US. In multivariable logistic regression model adjusting for known confounders, combined Sx+RT+Chemo was less likely to be received by female patients (OR 0.90, 95%CI 0.88–0.92) vs. male, non-White patients (OR 0.90, 95%CI 0.86–0.94) vs. White, patients treated at community hospitals (OR: 0.78, 95%CI 0.76–0.80) vs. academic centers, publicly-insured patients (OR 0.74, 95%CI 0.71–0.76) or uninsured patients (OR 0.54, 95%CI 0.50–0.58) vs. privately-insured, and patients living in the South (OR 0.88, 95%CI 0.85–0.91), Midwest (OR 0.83, 95% CI 0.80–0.86), and West (OR 0.85, 95%CI 0.81–0.88) compared to the Northeast. In multivariable Cox regression, significantly poorer survival was seen amongst non-metropolitan patients, community-based hospital patients, and publicly-insured and uninsured patients (vs. privately-insured), despite adjusting for prognostic factors. Conclusions: Only modest improvement in mOS of GBM patients has occurred across 2005–2020, with persistent disparities linked to sociodemographic and structural factors, whose redressal warrants multi-pronged efforts.
Keywords: high-grade glioma; neuro-oncology; racial disparities; molecular profiling; healthcare inequity; astrocytoma; brain cancer high-grade glioma; neuro-oncology; racial disparities; molecular profiling; healthcare inequity; astrocytoma; brain cancer

Share and Cite

MDPI and ACS Style

Sarfraz, Z.; Jayram, D.; Ozair, A.; Hodgson, L.; Bellur, S.; Maharaj, A.; Mansouri, A.; Ahluwalia, M.S. Association of Health Disparities with Glioblastoma Treatment and Outcomes: Insights from a 15-Year National Cohort (2005–2020). Brain Sci. 2025, 15, 556. https://doi.org/10.3390/brainsci15060556

AMA Style

Sarfraz Z, Jayram D, Ozair A, Hodgson L, Bellur S, Maharaj A, Mansouri A, Ahluwalia MS. Association of Health Disparities with Glioblastoma Treatment and Outcomes: Insights from a 15-Year National Cohort (2005–2020). Brain Sciences. 2025; 15(6):556. https://doi.org/10.3390/brainsci15060556

Chicago/Turabian Style

Sarfraz, Zouina, Diya Jayram, Ahmad Ozair, Lydia Hodgson, Shreyas Bellur, Arun Maharaj, Alireza Mansouri, and Manmeet S. Ahluwalia. 2025. "Association of Health Disparities with Glioblastoma Treatment and Outcomes: Insights from a 15-Year National Cohort (2005–2020)" Brain Sciences 15, no. 6: 556. https://doi.org/10.3390/brainsci15060556

APA Style

Sarfraz, Z., Jayram, D., Ozair, A., Hodgson, L., Bellur, S., Maharaj, A., Mansouri, A., & Ahluwalia, M. S. (2025). Association of Health Disparities with Glioblastoma Treatment and Outcomes: Insights from a 15-Year National Cohort (2005–2020). Brain Sciences, 15(6), 556. https://doi.org/10.3390/brainsci15060556

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop